Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)
Pharmaceutical company Celgene has requested that the US Patent and Trademark Office (USPTO) sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review (IPR) petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Celgene; Kyle Bass; Coalition for Affordable Drugs; IPR; PTAB; pharmaceuticals; generics; USPTO